180 Life Sciences Corp. — FY2020 Form 10-K
Filing identity and period: The supplied filing is for 180 Life Sciences Corp. (NASDAQ: ATNF; warrants: ATNFW), not FORUM MARKETS Inc. It reports the fiscal year ended December 31, 2020; it does not provide standalone fourth-quarter results. Filed July 9, 2021.
Business context and reporting period
180 Life Sciences is a clinical-stage biotechnology company developing therapeutics for chronic pain, inflammation and fibrosis through anti-TNF, synthetic cannabinoid analogue (SCA), and α7nAChR platforms. Its lead candidate, locally injected adalimumab for early-stage Dupuytren’s disease, completed a Phase 2b trial; data were still being verified and analyzed.
The November 6, 2020 business combination with KBL Merger Corp. IV was accounted for as a reverse recapitalization. FY2020 results primarily reflect 180’s historical operations before closing and combined operations afterward; FY2019 reflects a different historical entity mix. Accordingly, year-over-year comparisons are not fully like-for-like.
Financial performance and position
| Metric | FY2020 / Dec. 31, 2020 | FY2019 / Dec. 31, 2019 |
|---|---|---|
| Revenue | No revenue | No revenue |
| Research and development expense | $2.22 million | $1.98 million |
| General and administrative expense | $3.17 million | $5.61 million |
| Operating loss | $5.65 million | $20.86 million |
| Net loss | $10.88 million | $25.39 million |
| Net loss attributable to common stockholders | $12.01 million | $25.39 million |
| Cash used in operating activities | $3.87 million | $3.32 million |
| Cash and cash equivalents | $2.11 million | $0.08 million |
| Working capital deficit | $17.41 million | $8.89 million |
| Total debt reported in risk disclosures | $3.78 million | Not stated as a comparable total |
| Total assets / total liabilities | $55.53 million / $25.25 million | $51.88 million / $13.31 million |
There were no product sales, so operating margins are not meaningful. The lower 2020 net loss largely reflects the absence of a $12.96 million related-party stock-award modification expense recorded in 2019. FY2020 also included $2.58 million of losses on extinguishment of convertible notes and $1.82 million of non-cash derivative-liability fair-value expense. The company reported a $1.12 million deemed dividend related to Series A preferred stock, making loss attributable to common stockholders greater than net loss.
FY2020 investing cash inflow was $14.49 million, principally reflecting trust-account cash released in the business combination and cash acquired; financing cash outflow was $8.73 million, including $9.01 million for share redemptions. These transaction-related flows are not recurring operating cash generation. The balance sheet also included $4.44 million of derivative liabilities.
Material changes versus the prior comparable period
- R&D expense increased 12% to $2.22 million, with new and amended research commitments partly offset by the temporary pause in Evotec drug-discovery services.
- G&A expense declined 43% to $3.17 million, primarily reflecting a swing from bad-debt expense to recovery and lower travel and transaction-related costs.
- Operating cash use increased to $3.87 million from $3.32 million despite the lower reported net loss.
- The working capital deficit widened by $8.51 million to $17.41 million. The company reported an accumulated deficit of $48.36 million.
Outlook, risks and unusual items
- Funding and going concern: The auditor included a going-concern explanatory paragraph, citing significant losses, working-capital deficiency and dependence on new financing. Management said year-end cash was expected to fund planned operations only through Q3 2021 and disclosed an approximate $500,000 monthly cash requirement. No committed credit facility was in place.
- Subsequent financing: A February 2021 private offering raised approximately $11.7 million gross and $10.8 million net, but included 2.564 million shares and warrants for up to another 2.564 million shares. The company reported missing the registration-statement filing deadline and incurring contractual damages; the filing describes monthly damages of approximately $175,000 while the registration statement remained unfiled.
- Pipeline timing: Management expected top-line Dupuytren’s Phase 2b data in late Q3 or early Q4 2021. A frozen-shoulder Phase 2 feasibility study was being set up, with NIHR grant support of £250,000 and additional company funding planned. A POCD Phase 2 study was planned for Q2 2022; SCA clinical trials were anticipated as early as Q3 2022. These are plans, not assurances of completion or approval.
- Development and regulatory risk: The company had no FDA meetings or submissions for its platforms. Only anti-TNF trials had UK and Netherlands approvals; SCA and α7nAChR programs remained preclinical. Clinical results, regulatory approval, manufacturing, reimbursement and commercialization are uncertain.
- Controls and reporting: The company restated interim 2020 financial statements of predecessor KBL. Management identified material weaknesses in financial systems, accounting staffing and segregation of duties, written procedures, and period-end reporting controls; disclosure controls were also reported ineffective. The filing says remediation was planned, with assessment expected during 2021.
- Listing and registration matters: Nasdaq had issued notices concerning board independence and delayed filings. The company reported extensions and actions intended to regain compliance, but warned that delisting remained possible. It also disclosed registration-rights defaults and related penalties.
- Legal and contractual exposures: Disputes included a Cantor Fitzgerald claim seeking $1.5 million, litigation and counterclaims involving Tyche, and a former KBL executive’s acceleration claim on a $371,178 note plus contractual damages. The company disputed claims and stated outcomes were uncertain. Other commitments include university research payments, license milestones and related-party consulting obligations.
- Other balance-sheet and dilution risks: Intangible assets, in-process R&D and goodwill together represented most reported assets; impairment could materially affect reported results. Convertible securities, warrants, registration penalties and further equity financing may increase dilution. The company had no dividend history and did not expect near-term dividends.
The 2020 financial statements received an unqualified audit opinion, but that opinion does not address the effectiveness of internal control. The auditor emphasized substantial doubt about the company’s ability to continue as a going concern.
Important facts for investors to verify
- Confirm the filing issuer and ticker: the document identifies 180 Life Sciences Corp. (ATNF), not FORUM MARKETS Inc.
- Check subsequent cash balances, cash burn, financing proceeds and liabilities against the stated Q3 2021 runway and monthly cash requirement.
- Verify the status, results and regulatory plans for the Dupuytren’s Phase 2b trial and the planned frozen-shoulder, POCD and SCA programs.
- Review whether registration statements were filed and effective, whether contractual penalties were paid or accrued, and the current Nasdaq listing status.
- Assess remediation of material weaknesses, the circumstances and effects of the predecessor’s interim restatements, and the risk of further reporting errors.
- Review current status and potential exposure of the Cantor, Tyche, former-executive note and other legal disputes, along with related-party arrangements and financing-related dilution.